ArticleJTO clinical and research reports2025
Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.
Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: For patients with limited-stage SCLC (LS-SCLC), tumor burden is a predictor of clinical outcomes, but there are no known data exploring whether tumor burden is a predictor of clinical outcomes in relapsed SCLC. Methods: In this retrospective correlative study analyzing a cohort of 93 patients with relapsed SCLC, total body tumor volume at time of relapse (TV), progression-free survival (PFS), and overall survival (OS) were calculated and a Cox proportional hazards model was used to evaluate the relationship between TV and PFS and OS. Results: A total of 93 patients with relapsed SCLC were analyzed, of whom 70% initially had extensive-stage SCLC (ES-SCLC) and 30% initially had LS-SCLC. Eastern Cooperative Oncology Group performance status and receipt of second-line therapy were significantly associated with OS in a linear fashion ( Conclusions: TV was observed to be a predictor of OS in patients with relapsed SCLC. Further studies are needed to evaluate whether initiation of standard systemic therapy at lower TV is able to consistently improve PFS and OS in relapsed SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.